Supply of Ready-to-Use Cancer Treatment Medicines

This framework agreement covers the supply of aseptically prepared systemic anti-cancer therapy drugs manufactured in batch form and delivered in ready-to-administer presentations with pre-determined dose bands. The supplier will manufacture and deliver both standardized cancer treatment medicines and patient-specific formulations, including those prepared for continuous intravenous applications (CIVAs). The medicines must meet pharmaceutical standards for sterile preparation and be suitable for immediate clinical use. Suppliers should have expertise in aseptic manufacturing processes, batch production capabilities, and experience in handling cytotoxic and specialized oncology pharmaceuticals.